We are live on ! Find out more
GA

Geneva Advisors Portfolio holdings

AUM $5.81B
1-Year Est. Return 23.71%
This Fund
S&P 500
This Quarter Est. Return
+7.04%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
10 Year Est. Return
AUM
$5.37B
AUM Growth
+$62.8M
Cap. Flow
-$112M
Cap. Flow %
-2.09%
Top 10 Hldgs %
20.35%
Holding
855
New
121
Increased
189
Reduced
310
Closed
120

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$45.7M
2
IDXX icon
Idexx Laboratories
IDXX
+$34.3M
3
CAH icon
Cardinal Health
CAH
+$30.2M
4
AMAT icon
Applied Materials
AMAT
+$24.5M
5
ELV icon
Elevance Health
ELV
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 18.73%
2 Financials 15.53%
3 Industrials 13.23%
4 Consumer Discretionary 12.83%
5 Technology 10.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARUN
301
DELISTED
ARUBA NETWORKS, INC.
ARUN
$835K 0.02%
45,951
+22,789
+98% +$454K
PSX icon
302
Phillips 66
PSX
$96.2B
$833K 0.02%
11,617
-1,266
-10% -$93.4K
MELI icon
303
Mercado Libre
MELI
$99.4B
$832K 0.02%
6,520
-31,894
-83% -$4.03M
DDC
304
DELISTED
Dominion Diamond Corporation
DDC
$828K 0.02%
46,100
-2,025
-4% -$31.4K
SPSC icon
305
SPS Commerce
SPSC
$3.06B
$826K 0.02%
29,178
+3,328
+13% +$95.3K
N
306
DELISTED
Netsuite Inc
N
$821K 0.02%
+7,520
New +$768K
EPHE icon
307
iShares MSCI Philippines ETF
EPHE
$150M
$806K 0.02%
21,090
-5,825
-22% -$222K
LOW icon
308
Lowe's Companies
LOW
$116B
$785K 0.01%
11,417
+440
+4% +$26.3K
TEVA icon
309
Teva Pharmaceuticals
TEVA
$43.2B
$777K 0.01%
13,508
-3,442
-20% -$192K
BAP icon
310
Credicorp
BAP
$29.7B
$776K 0.01%
4,847
-1,791
-27% -$284K
LOCK
311
DELISTED
LifeLock, Inc.
LOCK
$773K 0.01%
+41,758
New +$689K
FCX icon
312
Freeport-McMoran
FCX
$110B
$765K 0.01%
32,730
-16,923
-34% -$467K
WBD icon
313
Warner Bros
WBD
$72.2B
$755K 0.01%
21,916
-9,349
-30% -$324K
VO icon
314
Vanguard Morningstar Mid-Cap ETF
VO
$109B
$751K 0.01%
24,320
+460
+2% +$13.9K
SWC
315
DELISTED
Stillwater Mining Co
SWC
$747K 0.01%
50,695
-2,290
-4% -$31.4K
CE icon
316
Celanese
CE
$4.89B
$742K 0.01%
12,369
XNCR icon
317
Xencor
XNCR
$2.09B
$734K 0.01%
45,741
+6,822
+18% +$79.1K
GWW icon
318
W.W. Grainger
GWW
$61.7B
$725K 0.01%
2,846
VEDL
319
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
$718K 0.01%
52,838
-3,584
-6% -$54.8K
DUK icon
320
Duke Energy
DUK
$94.5B
$710K 0.01%
8,494
-56
-0.7% -$4.52K
PSA.PRR
321
DELISTED
PUBLIC STORAGE DEPOSITORY SH REPSTG 1/1000TH PFD SER R
PSA.PRR
$708K 0.01%
27,215
+3
+0% +$78
BRFS
322
DELISTED
BRF SA
BRFS
$702K 0.01%
30,070
-14,425
-32% -$353K
SPG icon
323
Simon Property Group
SPG
$69.7B
$702K 0.01%
3,854
-884
-19% -$157K
BSTC
324
DELISTED
BioSpecifics Technologies Corp.
BSTC
$692K 0.01%
17,916
+1,047
+6% +$39.9K
BP icon
325
BP
BP
$107B
$687K 0.01%
21,734
-4,377
-17% -$147K

Similar funds

Geneva Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Geneva Advisors held 855 positions worth $5.37B, up 1.2% from $5.31B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Geneva Advisors's Q4 2014 filing shows 121 new, 189 increased, 310 reduced and 120 closed positions. Its largest new stake was Idexx Laboratories: 488,650 shares worth $36.2M. The largest sale was LyondellBasell Industries, an estimated $73.1M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 15% a quarter earlier, followed by Financials and Industrials.

  • Geneva Advisors's largest Q4 2014 buy was Idexx Laboratories: 488,650 shares worth $36.2M.
  • Geneva Advisors added most to Alibaba in Q4 2014, an estimated $45.7M increase.
  • Geneva Advisors's biggest Q4 2014 reduction was LyondellBasell Industries, cutting an estimated $73.1M.
  • Geneva Advisors fully exited Community Health Systems in Q4 2014, selling an estimated $13M.
  • Geneva Advisors's ten largest holdings make up 20% of its $5.37B portfolio in Q4 2014.
  • Geneva Advisors opened 121 new positions and closed 120 in Q4 2014.
  • Geneva Advisors's portfolio value rose 1.2% quarter-over-quarter to $5.37B.

Based on Geneva Advisors's 13F filing for Q4 2014, filed 2 Feb 2015.